BetterLife Pharma (BETRF) Share-based Compensation (2011 - 2026)
BetterLife Pharma (BETRF) posted Share-based Compensation of $111564.8 for Q2 2026, up 296.22% on a QoQ basis from $28157.3 in Q3 2025, and up 147.5% year-over-year from $45075.8 in Q2 2025.
Powered by 
Analysis
BetterLife Pharma (BETRF) Share-based Compensation (2011 - 2026) Analysis & Trends
BetterLife Pharma has reported Share-based Compensation for 13 years, with the latest figure at $111564.8 in Q2 2026.
- On a quarterly basis, Share-based Compensation rose 147.5% year-over-year to $111564.8 in Q2 2026; TTM through Apr 2026 was $306632.8, a 12.99% decrease from a year earlier, with the FY2026 full-year figure at $121925.9, down 91.81% from the prior year.
- Share-based Compensation was $111564.8 for Q2 2026 at BetterLife Pharma, up from $28157.3 in the prior quarter.
- The five-year high for Share-based Compensation was $1.2 million in Q2 2024, with the low at $17919.7 in Q3 2024.
- Average Share-based Compensation over 5 years is $206529.6, with a median of $115061.3 recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 1618.87% in 2024, then sank 96.24% in 2025.
- Over 5 years, Share-based Compensation stood at $108614.2 in 2022, then retreated by 23.73% to $82840.5 in 2023, then soared by 102.28% to $167568.9 in 2024, then tumbled by 83.2% to $28157.3 in 2025, then soared by 296.22% to $111564.8 in 2026.
- The last three Share-based Compensation figures came in at $111564.8 (Q2 2026), $28157.3 (Q3 2025), and $45075.8 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn | 83.34 Mn |
| 10 | BetterLife Pharma | 31.61 Mn | 31.59 Mn | - | 111,564.82 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 111,564.82 |
| Jul 31, 2025 | 28,157.29 |
| Apr 30, 2025 | 45,075.83 |
| Jan 31, 2025 | 121,834.85 |
| Oct 31, 2024 | 167,568.89 |
| Jul 31, 2024 | 17,919.66 |
| Apr 30, 2024 | 1.20 Mn |
| Jan 31, 2024 | 45,469.20 |
| Oct 31, 2023 | 82,840.48 |
| Jul 31, 2023 | 173,969.62 |
| Apr 30, 2023 | 69,664.25 |
| Jan 31, 2023 | 118,557.86 |
| Oct 31, 2022 | 108,614.20 |
| Jul 31, 2022 | 200,092.72 |
| Apr 30, 2022 | 307,568.04 |
| Jan 31, 2022 | 508,136.26 |
| Oct 31, 2021 | 140,946.80 |
| Jul 31, 2021 | 159,852.43 |
| Apr 30, 2021 | 170,519.00 |
| Jan 31, 2021 | 213,435.98 |